Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Quetiapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.85 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.85 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.85 |
| ▸ | DRD3 | P35462 | 3/20 | 0.85 |
| ▸ | DRD4 | P21917 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.85 |
| ▸ | HTR1A | P08908 | 2/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.85 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.85 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.85 |
| ▸ | DRD1 | P21728 | 2/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.85 |
| ▸ | HRH1 | P35367 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quetiapine SCHEMBL29487500 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL122596 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL31678628 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL4962023 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL390694 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL30990390 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL5325208 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL678457 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL41338 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL5070765 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3718 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| CN-224221240-U | Quetiapine fumarate tablet medicament column type hopper mixer | 华裕(无锡)制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260034151-A1 | TREATMENT OF FRAGILE X SYNDROME AND AUTISM SPECTRUM DISORDER WITH CANNABIDIOL | HARMONY BIOSCIENCES MANAGEMENT, INC. (US) | 2026-02-05 | — | — | US | claimed |
| US-20250288539-A1 | TREATMENT OF FRAGILE X SYNDROME AND AUTISM SPECTRUM DISORDER WITH CANNABIDIOL | HARMONY BIOSCIENCES MANAGEMENT, INC. (US) | 2025-09-18 | — | — | US | claimed |
| US-20250275924-A1 | Anticholinergic Agents and Muscarinic Agonists for the Treatment of Demodex Related Conditions | ATTILLAPS HOLDINGS INC. | 2025-09-04 | — | — | US | claimed |
| US-20250268823-A1 | Aqueous Quetiapine Solutions | RELIIS LTD. (AU) | 2025-08-28 | — | — | US | claimed |
| CN-120136813-A | Deuterium-labeled quetiapine fumarate isotope compound, preparation method thereof and food detection method | 曼哈格(上海)生物科技有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-120114403-A | Quetiapine fumarate sustained-release composition and preparation method thereof | 上海国创医药股份有限公司 | 2025-06-10 | — | — | CN | claimed |
| EP-4511123-A1 | ANTICHOLINERGIC AGENTS AND MUSCARINIC AGONISTS FOR THE TREATMENT OF DEMODEX RELATED CONDITIONS | Attillaps Holdings Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| WO-2003020200-A2 | A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME | NEW RIVER PHARMACEUTICALS INC. (US) | 2003-03-13 | — | — | WO | claimed |
| WO-2003018009-A1 | A COMBINATION OF QUETIAPINE AND ZOLMITRIPTAN | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| WO-2002102297-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS | MUELLER NORBERT (DE) | 2002-12-27 | — | — | WO | claimed |
| US-20020192300-A1 | Transdermal and topical administration of antipsychotic agents using basic enhancers | DERMATRENDS, INC. | 2002-12-19 | — | — | US | claimed |
| US-20020142050-A1 | Porous drug matrices and methods of manufacture thereof | ACUSPHERE INC. | 2002-10-03 | — | — | US | claimed |
| EP-1180020-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | Acusphere, Inc. (US) | 2002-02-20 | — | — | EP | claimed |
| WO-2000072827-A9 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE INC (US) | 2002-01-31 | — | — | WO | claimed |
| CN-1331580-A | Conversion of liquid-filled gelatin capsules into controlled release systems with multiple coatings | ALZA CORP (US) | 2002-01-16 | — | — | CN | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |